Qiagen N.V.

BATS-CHIXE:QIAD Stock Report

Market Cap: €9.2b

Qiagen Valuation

Is QIAD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of QIAD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: QIAD (€41.09) is trading below our estimate of fair value (€59.6)

Significantly Below Fair Value: QIAD is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for QIAD?

Key metric: As QIAD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for QIAD. This is calculated by dividing QIAD's market cap by their current earnings.
What is QIAD's PE Ratio?
PE Ratio103.4x
EarningsUS$92.93m
Market CapUS$9.61b

Price to Earnings Ratio vs Peers

How does QIAD's PE Ratio compare to its peers?

The above table shows the PE ratio for QIAD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.1x
ERGO Ergomed
46.7x14.2%UK£701.1m
HVO hVIVO
7.7x-15.2%UK£134.7m
HIK Hikma Pharmaceuticals
19.2x12.7%UK£4.4b
ERF Eurofins Scientific
26.9x18.3%€8.8b
QIAD Qiagen
103.4x34.4%€9.6b

Price-To-Earnings vs Peers: QIAD is expensive based on its Price-To-Earnings Ratio (103.4x) compared to the peer average (17.9x).

Price to Earnings Ratio vs Industry

How does QIAD's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
No. of Companies3PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: QIAD is expensive based on its Price-To-Earnings Ratio (103.4x) compared to the European Life Sciences industry average (37.3x).

Price to Earnings Ratio vs Fair Ratio

What is QIAD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

QIAD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio103.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate QIAD's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst QIAD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€41.09
€48.00
+16.8%
8.0%€56.93€40.32n/a17
Nov ’25€38.66
€46.68
+20.7%
7.8%€55.41€40.46n/a17
Oct ’25€40.32
€46.17
+14.5%
7.8%€54.34€39.68n/a17
Sep ’25n/a
€46.52
0%
7.8%€54.76€39.99n/a17
Aug ’25n/a
€46.80
0%
8.4%€55.60€40.60n/a17
Jul ’25n/a
€47.41
0%
9.0%€57.80€40.94n/a17
Jun ’25n/a
€46.55
0%
9.3%€56.89€40.30n/a16
May ’25€38.12
€47.25
+24.0%
9.5%€57.85€39.75n/a16
Apr ’25n/a
€47.66
0%
8.9%€57.32€39.38n/a16
Mar ’25n/a
€47.42
0%
8.9%€57.03€39.19n/a16
Feb ’25€40.87
€47.71
+16.7%
9.3%€57.05€40.41n/a16
Jan ’25n/a
€46.16
0%
10.1%€56.35€39.45n/a17
Dec ’24€38.20
€45.79
+19.9%
10.6%€56.68€39.68n/a16
Nov ’24€36.53
€48.03
+31.5%
11.8%€58.53€40.97€38.6615
Oct ’24€39.55
€51.00
+29.0%
8.8%€58.51€41.44€40.3215
Sep ’24n/a
€49.98
0%
10.2%€60.48€40.16n/a14
Aug ’24n/a
€49.74
0%
10.4%€59.31€39.38n/a14
Jul ’24€42.41
€51.18
+20.7%
10.4%€60.94€40.47n/a14
Jun ’24€43.82
€51.92
+18.5%
10.3%€61.32€40.72n/a13
May ’24€41.60
€52.45
+26.1%
8.1%€58.26€44.17€38.1211
Apr ’24€43.30
€53.45
+23.4%
10.4%€60.57€41.52n/a12
Mar ’24€44.98
€52.46
+16.6%
10.2%€59.54€40.81n/a12
Feb ’24€46.15
€51.31
+11.2%
9.7%€59.41€40.73€40.8712
Jan ’24€48.36
€54.44
+12.6%
9.2%€63.85€43.77n/a11
Dec ’23€48.78
€54.44
+11.6%
9.2%€63.85€43.77€38.2011
Nov ’23€45.72
€57.71
+26.2%
10.7%€65.87€45.16€36.5311

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.80

7D

1.9%

1Y

12.1%

hVIVO

UK£134.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.20

7D

-16.8%

1Y

2.1%

Regeneron Pharmaceuticals

US$80.6b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$750.19

7D

0.5%

1Y

-5.7%